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Abstract
Background: The use of Routine Outcome Monitoring (ROM) in mental health care has increased widely during
the past decade. Little is known, however, on the implementation and applicability of ROM outcome in daily
clinical practice. In the Netherlands, an extensive ROM-protocol for patients with psychotic disorders has been
implemented over the last years (ROM-Phamous). The current study investigated to what extent ROM results
translate to daily clinical practice. Therefore, we investigated whether clinical problems as identified with ROM
were detected and used in the treatment of patients with psychotic disorders.
Methods: Out of the ROM database of 2010 (n = 1040), a random sample of 100 patients diagnosed with a
psychotic disorder was drawn. ROM-data used in this study included a physical examination, laboratory tests,
interviews and self-report questionnaires. Based on these data, the prevalence of positive and negative symptoms,
psychosocial problems and cardiovascular risk factors was determined. Next, we investigated whether these
problems, as identified with ROM, were reflected in the treatment plans of patients, as an indication of the use of
ROM in clinical practice.
Results: The sample consisted of 63 males and 37 females. The mean age was 44 and the mean duration of illness
was 17.7 years. The prevalence of positive and negative symptoms, psychosocial problems and cardiovascular risk
factors ranged from 11 to 86 %. In the majority of cases, problems as identified with ROM were not reflected in the
treatment plans of patients.
Conclusions: We found a substantial discrepancy between the ROM measurements and the treatment plans, i.e.
low rates of detection of symptoms, psychosocial problems and cardiovascular risk factors in the treatment plans,
even though these problems were identified with ROM. The opposite occurred as well, where problems were
reflected in the treatment plans but not identified with ROM. Thus, ROM and daily clinical practice appear to be
two separate processes, whereas ideally they should be integrated. Strong efforts should be made to integrate ROM
and consequent treatment activities. Such integration may help to provide patients with adequate and customized
care and simultaneously minimize under- and over-treatment.
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Background
Psychiatric disorders with a psychotic component include
schizophrenia, schizophreniform disorder, schizoaffective
disorder, delusional disorder, brief psychotic disorder,
psychotic disorder not otherwise specified, and psychosis
associated with substance use or medical conditions,
according to the DSM-IV-TR classification system [1].
Core features of most psychotic disorders are positive
symptoms (hallucinations, illusions, delusions, incoher-
ent thoughts and problems with logical thinking) and
negative symptoms (loss of initiative, flat affect, poverty
of speech, lack of motivation and social withdrawal) [1, 2].
The prevalence of schizophrenia worldwide is in the range
of 1.4 to 4.6 per 1000 people, pending a large burden on
patients and society [2, 3].
Both positive symptoms and negative symptoms greatly
interfere with daily life functioning [2]. Moreover, patients
have reported daytime activities, psychotic symptoms,
psychological distress, company and intimate relationships
as the most frequently occurring unmet needs [4]. As a
result, patients with psychotic disorders often experience
reduced quality of life [5]. Furthermore, life expectancy is
significantly lower (20–25 years) [6–9] and mortality rates
are 2–3 times greater than in the general population [10].
Especially premature cardiovascular disease has been
associated with lower life expectancy and high mortal-
ity rates [11]. In patients with psychotic disorders, risk
factors for cardiovascular disease are often present,
such as obesity (45–55 %), smoking (50–80 %), diabetes
mellitus (10–15 %), hypertension (19–58 %) and dysli-
pidaemia (25–69 %) [12]. Of note, these medical prob-
lems often go undetected or untreated in patients with
severe mental illness [13].
Routine Outcome Monitoring (ROM) in adult patients
may improve the diagnostics and treatment of psychi-
atric problems, according to a review of Carlier et al.
[14]. However, several other studies claim that few clini-
cians in psychiatry use the outcome of ROM in their
day-to-day work [15, 16]. During the last decade, the use
of ROM in mental health care has increased widely. This
increase is partly due to demands of health insurance
companies [17]. Little is known, however, on the imple-
mentation of ROM-measurements and the applicability
of its outcome in daily clinical practice.
Over the last years, a protocol called the Routine Out-
come Monitoring Pharmacotherapy Monitoring and Out-
come Survey (ROM-Phamous) has been developed in the
Northern Netherlands (Bartels-Velthuis A, Visser E, Arends
J, Pijnenborg G, Wunderink L, Jörg F, et al: Pharmacotherapy
Monitoring and Outcome Survey: the annual PHAMOUS
screening of physical and mental health of patients with
psychotic disorders, in preparation) [18], to optimize psy-
chosocial interventions and pharmacotherapy. This proto-
col prescribes a yearly assessment with a comprehensive
battery of instruments to monitor psychiatric symptom
severity, medication-efficacy and physical health, social
functioning, quality of life and service user satisfaction in
all patients with psychotic disorders.
The present study investigated to what extent ROM
results of patients with a psychotic disorder translate to
daily clinical practice. To this end, we investigated whether
clinical problems as identified with ROM were reflected in
the treatment plans of patients. The frequently occurring
clinical problems that we chose to investigate, were posi-
tive and negative symptoms, problems with social func-
tioning, problems with daily activities and cardiovascular
risk factors. As previous studies have shown that clinicians
do not always use ROM outcome in their day-to-day work
[15, 16] and various problems in patients with a psychotic
disorder remain undetected or untreated [13], we expect a
discrepancy between problems identified with ROM and
the problems that are reflected in the treatment plans of
patients with a psychotic disorder.
Methods
Subjects
In 2010, the ROM-Phamous database contained informa-
tion of 1040 patients who received care at Lentis Psychiatric
Institute or at the University Center of Psychiatry of the
University Medical Center Groningen (UMCG) in the
Netherlands. The current study could be performed with-
out extra assessments of the patients, since the ROM-data
were available at the start of the study. The Medical Ethical
Committee of the UMCG has confirmed that anonymized
ROM-Phamous data may be used for scientific research
and, therefore, this study did not require additional ethics
approval. The study was executed in line with local legisla-
tion and the Declaration of Helsinki.
Procedure
The ROM-Phamous screening protocol is extensive and
contains a battery of instruments, including a physical
examination (weight, height, abdominal circumference,
blood pressure, movement tests), laboratory tests (includ-
ing glucose and cholesterol levels), an interview (PANSS
[19]), and clinician-rated and self-report questionnaires
(HoNOS [20], MANSA [21], SRA-34 [22]). In our cross-
sectional study, the prevalence of positive and negative
symptoms, psychosocial problems and cardiovascular risk
factors was calculated with the available ROM-data. Next,
the psychiatric treatment plans, obtained from the Elec-
tronic Patient File (EPF), were investigated. The first treat-
ment plan written after the ROM-screening was used for
the study. Treatment plans of patients receiving care at
Lentis Psychiatric Institute were retrieved by a clinician of
this institute (GW). Treatment plans of patients receiving
care at the University Medical Center Groningen were
retrieved by a clinician of this hospital (RB). The heads
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of the departments at Lentis Psychiatric Institute and the
University Medical Center Groningen provided permission
to access the treatment plans for this study. All treatment
plans were stored anonymously and investigated by an
independent researcher (MT). The investigation of the
treatment plans had to be done manually and was a
time consuming process. For this reason, we chose to
investigate a random sample of 100 patients in this first
exploratory study. This random sample of 100 patients
was drawn out of the complete ROM-Phamous data-
base, with the option ‘random sample of cases’ (under
‘select cases’) of IBM SPSS Statistics 20 [23].
Measures
Demographic ROM-data were used, including gender,
age and duration of illness. Demographic information of
patients in the sample was compared to all patients in
the ROM-database. Severity of psychiatric symptoms was
assessed using the Positive and Negative Syndrome Scale
Remission (PANSS-R) [24]. To assess positive symptoms,
the items P1 ‘delusions’, P2 ‘conceptual disorganization’
and P3 ‘hallucinations’ were used and for negative symp-
toms, the items N1 ‘blunted affect’, N4 ‘passive/apathetic
social withdrawal’ and N6 ‘lack of spontaneity and flow of
conversation’ were used. Symptomatic remission is de-
fined as ratings of mild (score 3) or less on all these items
over a 6-month period [24]. Therefore, a score of 4 or
higher on one or more of these items was defined as the
presence of positive and/or negative symptoms. Assess-
ment of psychosocial functioning, was based on the Dutch
versions of the clinician-rated Health of the Nations Out-
come Scale (HoNOS) and the self-report Manchester
Short Assessment of Quality of Life (MANSA). More spe-
cifically, to measure problems in social relationships, item
9 ‘Problems with relationships’ of the HoNOS and item 12
‘How satisfied are you with your social relationships?’ of
the MANSA were used. To measure problems with daily
activities and occupation, item 12 ‘Possibilities to use and
improve skills: occupational and free time’ of the HoNOS
and item 4 ‘How satisfied are you with your daily activ-
ities?’ of the MANSA were used. When the score on the
HoNOS item was 3 or higher (indicating a problem that
needs treatment) and/or the score on the MANSA item
was 3 or lower (indicating dissatisfaction in this area), this
was defined as a problem with social relationships/daily
activities or occupation. To investigate cardiovascular
risk factors, data from the physical examination were
used, including measurement of weight, height and
blood pressure, nicotine and cannabis use and add-
itional laboratory tests. The modifiable risk factors for
cardiovascular disease that were studied are overweight
(body mass index higher than 25 kg/m2), diabetes mellitus
(fasting plasma glucose levels >7.0 mmol/L), hypertension
(blood pressure levels >140/90 mmHg (without diabetes)
or >130/80 mmHg (with diabetes)) and dyslipidaemia (total
cholesterol >5 mmol/L (without diabetes) or >4.5 mmol/L
(with diabetes) and/or LDL-cholesterol >3 mmol/L
(without diabetes) or >2.5 mmol/L (with diabetes)).
These criteria were established by De Hert and others,
in collaboration with the European Psychiatric Associ-
ation [7], who have conducted extensive research on
cardiovascular risk factors in people with severe mental
illness. After calculating the prevalence of symptoms,
psychosocial problems and cardiovascular risk factors
with the ROM-data, the psychiatric treatment plans
were investigated. It was scored whether the investigated
problems were mentioned in the treatment plans: positive
symptoms, negative symptoms, problems in social func-
tioning, problems with daily activities, overweight, dia-
betes mellitus, hypertension, dyslipidaemia and smoking.
Data analysis
The anonymized data were analysed by an independent
researcher (MT). Descriptive statistics were performed
in IBM SPSS Statistics 20 [23]. For each investigated
problem area, patients were divided into four categories:
1) the problem was neither identified with ROM, nor
reflected in the treatment plan, 2) the problem was not
identified with ROM, but was reflected in the treatment
plan, 3) the problem was identified with ROM, but not
reflected in the treatment plan and 4) the problem was
both identified with ROM and reflected in the treatment
plan. Only patients of whom both the ROM-data and
the psychiatric treatment plan were available were in-
cluded in the analysis. Missing ROM-data were caused
by patients who did not show up for appointments or
refused to take part in (part of) the ROM-Phamous
screening. Missing treatment plans were partly due to
patients who stopped receiving care at our institution
fairly soon after their ROM-screening and therefore did
not have a new treatment plan. The reasons for the
remaining missing treatment plans are unknown, but
could be due to administrative problems or clinicians
who failed to write treatment plans.
Results
Problems identified with ROM
Patient characteristics and the prevalence of the investi-
gated problem areas, based on the ROM-data, are dis-
played in Table 1 for the selected sample. The total
amounts of patients were different for each problem
area, due to missing ROM-data. Most prevalent prob-
lems in our sample were positive symptoms, overweight,
dyslipidaemia and smoking. No significant differences were
found in gender distribution (X2 (1) = 0.026; p = 0.872), age
(t = 0.979; df = 1137; p = 0.426) and duration of illness
(t = −0.028; df = 896; p = 0.978) between the selected
sample and the other patients in the database.
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ROM and the treatment plan
The time between the ROM-screening and the draft of the
treatment plan ranged from 0 to 18 months (mean = 6.7;
sd = 4.9). Figure 1 depicts whether problems were identi-
fied with ROM and whether they were reflected in the
treatment plan. Only in a small amount of cases problems
were both detected with ROM and reflected in the treat-
ment plan (mean = 5; ranging from 1 patient to 16 pa-
tients between the different problem areas). In many
cases, problems were detected with ROM, but not
reflected in the treatment plan. This was especially
striking for positive and negative symptoms, over-
weight, dyslipidaemia and smoking (n = 21; n = 17; n = 43;
n = 40; n = 56, respectively). The opposite occurred as well,
where problems were not detected with ROM, but were
reflected in the treatment plans. This occurred most
frequently in problems with social functioning and
daily activities (n = 14; n = 34, respectively).
Discussion
This study investigated to what extent ROM results of
patients with a psychotic disorder translate to daily clinical
practice. We found a substantial discrepancy between the
ROM measurements and the treatment plans of patients,
i.e. low rates of detection of symptoms, psychosocial prob-
lems and cardiovascular risk factors in the treatment
plans, even though these problems were identified with
ROM. The opposite occurred as well, where problems
were reflected in the treatment plans but not identified
with ROM. These exploratory results suggest that ROM
and daily clinical practice are two separate processes,
whereas ideally they should be integrated. An effort should
be made to improve this integration, as this may help to
provide patients with more adequate and customized care
and simultaneously minimize under- and over-treatment.
Implementation of ROM in clinical practice
Positive and negative symptoms, psychosocial problems
and cardiovascular risk factors still occur relatively often
in this population suffering from psychotic disorders.
Our findings are in line with many other studies indicat-
ing that a high proportion of patients with psychotic dis-
orders have little or no social contact or friends and
experience difficulties getting involved in social activities
or work [4]. Also, the prevalence of modifiable cardio-
vascular disease risk factors in our study is comparable
with other studies in psychotic disorders [7, 12, 25].
Interestingly, whereas obesity was present in 66 % of pa-
tients, related problems such as diabetes mellitus and
hypertension only occurred in a small subset of the sam-
ple. These low prevalences may indicate that these prob-
lems are already detected and treated relatively well,
although these results should be replicated in a larger
sample. Taken together, our ROM-system is sensitive for
the detection of relevant problems in patients with a
psychotic disorder.
However, the most striking finding is that clinicians do
not adjust the treatment according to the ROM results.
Our findings illustrate that ROM is not implemented to
its full benefit in the healthcare provided for these pa-
tients. These findings also underline the notion that
merely introducing a ROM-system in mental health care
is not enough [26, 27], as research shows that few clini-
cians use the outcome of ROM in their day-to-day work
[15, 16]. There appear to be barriers and challenges in
the use of routine outcome data [28], including the fact
that clinicians are often overscheduled and experience
time pressure [28, 29]. This was also reflected in the sub-
stantial time gap between the ROM-screening and the
treatment plans of patients, found in the present study.
Clearly, the implementation of ROM results in the
treatment of patients must be improved. A first step
should be to have the interpretation of ROM-results and
the updating of the treatment plan within a limited time
frame. This would help to reduce the long time between
the ROM-screening and the draft of the treatment plan
that we found in our study. Also, to improve the stand-
ard of care, the decision making process of clinicians
Table 1 Patient characteristics and prevalence of problems in
the sample (n = 100), based on the ROM-data
Demographic information
Male/female 63/37 (n)
Mean age (SD) 44.0 (10.3) (years)




Psychotic disorder NOS 11
Number of antipsychotic agents n
No antipsychotic agents 10
One antipsychotic agent 75
Two or more antipsychotic agents 15
Symptoms and psychosocial problems
Positive symptoms 37.2 % (32/86)
Negative symptoms 24.4 % (21/86)
Problems with social functioning 24.2 % (24/99)
Problems with daily activities/occupation 13.1 % (13/99)
Cardiovascular risk factors
Overweight 66 % (62/94)
Diabetes mellitus type II 11.1 % (9/81)
Hypertension 10.9 % (10/92)
Dyslipidaemia 57.3 % (47/82)
Smoking 85.5 % (65/76)
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could be made more explicit and transparent. To this
end, all identified problems must be described in the
treatment plan. Next, considerations should be described
about whether or not treatment will be given. This will
help to avoid certain problems to be discussed repeat-
edly and, more importantly, will avoid that problems are
not taken into consideration. In addition, it should be
clearly stated when treatment is not given and whether
this is because the available treatment options did not work
or whether it is due to lack of availability of care. The first
issue should be addressed with treatment research and
strict adherence to treatment guidelines, whereas the latter
should be addressed with health care policy adjustments.
The focus of treatment
An interesting result of our study was the finding that in
some cases problems were reflected in the treatment
plan, but were not identified with ROM. This was mostly
seen in problems with social functioning and problems
with daily activities. Presumably, our ROM measures did
not pick up these signals or patients may not have reported
these problems due to lack of insight or an adjustment of
expectations to their chronic situation. Unexpectedly, we
found this discrepancy for positive symptoms as well. Pos-
sibly, positive symptoms are still mentioned as treatment
goals, even when symptoms do not interfere with daily life
functioning anymore and therefore are not detected with
ROM. In general, it is possible that positive symptoms and
psychosocial problems already receive much attention in
clinical practice. This could be because these problems usu-
ally stand out and are difficult to overlook. Apparently, the
clinician’s focus of treatment seems to be directed most
strongly on psychotic symptoms and psychosocial symp-
toms and less on negative symptoms and physical health.
Strengths and limitations
Strength of the study is the broad scope, as multiple
areas of functioning were investigated with ROM. More-
over, the sample is an epidemiologically representative
sample from the majority of patients with schizophrenia
in the province of Groningen, the Netherlands. Also, the
sample is representative for all patients in the ROM
database. There are some limitations of the study. Firstly,
our data was only retrieved from clinical records and we
did not explicitly ask clinicians about their decision making
process. It is therefore possible that certain problems
that were identified with ROM, were not reflected in the
treatment plan for specific reasons we are not aware of.
Lastly, the data was collected and scored by one independent
researcher. In future studies, data collection should be
done by at least two independent researchers to improve
reliability.
Fig. 1 Problems detected with ROM and the treatment plan. This graph depicts whether problems were detected with ROM and whether they
were reflected in the treatment plans of patients. The investigated problem areas are depicted on the x-as and the amount of patients is depicted
on the y-as. Patients with incomplete information (missing ROM-data and/or missing treatment plans) are not shown in the graph. The grey part
of the bars indicates the amount of patients of which a problem was neither detected with ROM, nor reflected in the treatment plan. The orange
part of the bars indicates the amount of patients of which a problem was not detected with ROM, but was reflected in the treatment plan. The
red part of the bars indicates the amount of patients of which a problem was detected with ROM, but was not reflected in the treatment plan.
The green part of the bars indicates the amount of patients of which a problem was both detected with ROM and reflected in the treatment plan.
(ROM = Routine Outcome Monitoring, TP = treatment plan, + = problem is detected/reflected, − = problem is not detected/reflected)
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Future research
This study prompts our mental health care organization
as well as others to actively investigate the current state
of affairs. We expect to see improvements in the imple-
mentation of ROM within the next years. All stake-
holders should aim to bridge the gap between ROM and
the treatment of patients as this may help to improve
the quality of care, especially in patients needing long
term care. To achieve this, it would be helpful to de-
velop software applications that can reduce time burdens
and make ROM outcome assessment more user-friendly
for clinicians and patients [28]. We are currently work-
ing on a tool that helps translate and interpret ROM
outcome and in addition offers suggestions for treatment
based on the most recent treatment guidelines. We hope
this can further improve the integration between ROM
and treatment.
Conclusions
Our study investigated to what extent ROM results of
patients with a psychotic disorder translate to daily clinical
practice. We found a substantial discrepancy between the
ROM measurements and the treatment plans of patients.
These exploratory results suggest that the connection be-
tween ROM and the treatment that patients receive is far
from optimal yet. Strong efforts should be made to inte-
grate routine outcome monitoring and consequent treat-
ment activities. Such integration may help to provide
patients with the most adequate and customized care and
simultaneously minimize under- and over-treatment.
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